Download PDF
Semin Thromb Hemost 2023; 49(03): 242-254
DOI: 10.1055/s-0042-1760330
Review Article

Clinical Studies with Anticoagulants that Have Changed Clinical Practice

Jack Hirsh
1   Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Tim A.C. de Vries
2   Heart Center, Department of Clinical and Experimental Cardiology and Cardiothoracic Surgery, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands
3   Heart Failure and Arrhythmias, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands
4   Department of Cardiology, Rijnstate Hospital, Arnhem, The Netherlands
,
John W. Eikelboom
1   Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
5   Division of Hematology and Thromboembolism, Department of Medicine, Population Health Research Institute, Hamilton, Ontario, Canada
6   Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
,
Vinai Bhagirath
1   Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
5   Division of Hematology and Thromboembolism, Department of Medicine, Population Health Research Institute, Hamilton, Ontario, Canada
6   Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
,
Noel C. Chan 
1   Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
5   Division of Hematology and Thromboembolism, Department of Medicine, Population Health Research Institute, Hamilton, Ontario, Canada
6   Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Anticoagulant therapy is the cornerstone of treatment and prevention of arterial and venous thromboembolism. Taking a historical perspective, starting in the 1960s, and progressing through to 2022, we discuss key clinical trials of anticoagulants that have changed clinical practice, and examine obstacles encountered in bringing these anticoagulants to the clinic. The design of some of the early studies that shaped clinical practice was poor by current standards, but their results were influential because nothing better was available. Both heparin and vitamin K antagonists had been in clinical use for several decades before well-designed trials in the 1980s optimized their dosing and enhanced their safety and efficacy. Low-molecular-weight heparin then replaced unfractionated heparin because it had a more predictable dose–response and a longer half-life, thereby allowing it to be used conveniently in out-of-hospital settings. More recently, direct oral anticoagulants became the oral anticoagulants of choice for most indications because they were shown to be at least as safe and effective as vitamin K antagonists when used in fixed doses without the need for laboratory monitoring. The design of the trials that led to the approval of the direct oral anticoagulants was excellent, but further studies are required to optimize their dosing in selected patients who were underrepresented in these trials.

Keywords

anticoagulation - heparin - warfarin - direct oral anticoagulants - venous thromboembolism - atrial fibrillation - bleeding


Publication History

Article published online:
05 January 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Bauer G, Bostrom H, Jorpes E, Kallner S. Intramuscular administration of heparin. Acta Med Scand 1949; 136 (03) 188-198
    CrossrefPubMedGoogle Scholar
  • 2 Salzman EW, Deykin D, Shapiro RM, Rosenberg R. Management of heparin therapy: controlled prospective trial. N Engl J Med 1975; 292 (20) 1046-1050
    CrossrefPubMedGoogle Scholar
  • 3 Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287 (07) 324-327
    CrossrefPubMedGoogle Scholar
  • 4 Hirsh J, Anand SS, Halperin JL, Fuster V. American Heart Association. Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Circulation 2001; 103 (24) 2994-3018
    CrossrefPubMedGoogle Scholar
  • 5 Hull RD, Raskob GE, Hirsh J. et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315 (18) 1109-1114
    CrossrefPubMedGoogle Scholar
  • 6 Kearon C, Ginsberg JS, Julian JA. et al; Fixed-Dose Heparin (FIDO) Investigators. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006; 296 (08) 935-942
    CrossrefPubMedGoogle Scholar
  • 7 Wessler S, Gitel SN, Bank H, Martinowitz U, Stephenson RC. An assay of the antithrombotic action of warfarin: its correlation with the inhibition of stasis thrombosis in rabbits. Thromb Haemost 1979; 40 (03) 486-498
    PubMedGoogle Scholar
  • 8 Gitel SN, Wessler S. Dose-dependent antithrombotic effect of warfarin in rabbits. Blood 1983; 61 (03) 435-438
    CrossrefPubMedGoogle Scholar
  • 9 Gallus A, Jackaman J, Tillett J, Mills W, Wycherley A. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986; 2 (8519): 1293-1296
    CrossrefPubMedGoogle Scholar
  • 10 Hull RD, Raskob GE, Rosenbloom D. et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322 (18) 1260-1264
    CrossrefPubMedGoogle Scholar
  • 11 Théroux P, Ouimet H, McCans J. et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319 (17) 1105-1111
    CrossrefPubMedGoogle Scholar
  • 12 Neri Serneri GG, Rovelli F, Gensini GF, Pirelli S, Carnovali M, Fortini A. Effectiveness of low-dose heparin in prevention of myocardial reinfarction. Lancet 1987; 1 (8539): 937-942
    CrossrefPubMedGoogle Scholar
  • 13 Macmahon S, Collins R, Knight C, Yusuf S, Peto R. Reduction in major morbidity and mortality by heparin in acute myocardial-infarction. BMJ 1989; 61 (01) 118-118
    PubMedGoogle Scholar
  • 14 Chan N, Sobieraj-Teague M, Eikelboom JW. Direct oral anticoagulants: evidence and unresolved issues. Lancet 2020; 396 (10264): 1767-1776
    CrossrefPubMedGoogle Scholar
  • 15 Wright IS, Beck DF, Marple CD. Myocardial infarction and its treatment with anticoagulants; summary of findings in 1031 cases. Lancet 1954; 266 (6802): 92-95
    CrossrefPubMedGoogle Scholar
  • 16 Poller L, Taberner DA. Dosage and control of oral anticoagulants: an international collaborative survey. Br J Haematol 1982; 51 (03) 479-485
    CrossrefPubMedGoogle Scholar
  • 17 Hirsh J. Solving the mystery of excessive warfarin-induced bleeding: a personal historical perspective. Thromb Haemost 2014; 112 (05) 853-856
    PubMedGoogle Scholar
  • 18 Hull R, Delmore T, Genton E. et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301 (16) 855-858
    CrossrefPubMedGoogle Scholar
  • 19 Hull R, Delmore T, Carter C. et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982; 306 (04) 189-194
    CrossrefPubMedGoogle Scholar
  • 20 Poller L. A national standard for anticoagulant therapy. The Manchester comparative reagent. Lancet 1967; 1 (7488): 491-493
    CrossrefPubMedGoogle Scholar
  • 21 Hull R, Hirsh J, Jay R. et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307 (27) 1676-1681
    CrossrefPubMedGoogle Scholar
  • 22 Turpie AG, Gunstensen J, Hirsh J, Nelson H, Gent M. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1988; 1 (8597): 1242-1245
    CrossrefPubMedGoogle Scholar
  • 23 Hirsh J, Poller L, Deykin D, Levine M, Dalen JE. Optimal therapeutic range for oral anticoagulants. Chest 1989; 95 (2, Suppl): 5S-11S
    CrossrefPubMedGoogle Scholar
  • 24 Poller L. International normalized ratios (INR): the first 20 years. J Thromb Haemost 2004; 2 (06) 849-860
    CrossrefPubMedGoogle Scholar
  • 25 ACCP-NHLBI National Conference on Antithrombotic Therapy. American College of Chest Physicians and the National Heart, Lung and Blood Institute. Chest 1986; 89 (2, Suppl): 1S-106S
    PubMedGoogle Scholar
  • 26 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146 (12) 857-867
    CrossrefPubMedGoogle Scholar
  • 27 Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol 2003; 41 (4, Suppl S): 62S-69S
    CrossrefPubMedGoogle Scholar
  • 28 Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59 (06) 1239-1245
    CrossrefPubMedGoogle Scholar
  • 29 Kakkar VV, Murray WJ. Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study. Br J Surg 1985; 72 (10) 786-791
    CrossrefPubMedGoogle Scholar
  • 30 Turpie AG, Levine MN, Hirsh J. et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986; 315 (15) 925-929
    CrossrefPubMedGoogle Scholar
  • 31 Koopman MM, Prandoni P, Piovella F. et al; The Tasman Study Group. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334 (11) 682-687
    CrossrefPubMedGoogle Scholar
  • 32 Levine M, Gent M, Hirsh J. et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334 (11) 677-681
    CrossrefPubMedGoogle Scholar
  • 33 Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000; 355 (9219): 1936-1942
    CrossrefPubMedGoogle Scholar
  • 34 Hirsh J, Eikelboom JW, Chan NC. Fifty years of research on antithrombotic therapy: achievements and disappointments. Eur J Intern Med 2019; 70: 1-7
    CrossrefPubMedGoogle Scholar
  • 35 Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335 (11) 775-782
    CrossrefPubMedGoogle Scholar
  • 36 Greinacher A, Lubenow N. Recombinant hirudin in clinical practice: focus on lepirudin. Circulation 2001; 103 (10) 1479-1484
    CrossrefPubMedGoogle Scholar
  • 37 Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban-915 Investigators. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003; 163 (15) 1849-1856
    CrossrefPubMedGoogle Scholar
  • 38 Lewis BE, Wallis DE, Berkowitz SD. et al; ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103 (14) 1838-1843
    CrossrefPubMedGoogle Scholar
  • 39 Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008; 99 (05) 830-839
    PubMedGoogle Scholar
  • 40 Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton II JW. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29 (30) 7095-7101
    CrossrefPubMedGoogle Scholar
  • 41 Stone GW, McLaurin BT, Cox DA. et al; ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355 (21) 2203-2216
    CrossrefPubMedGoogle Scholar
  • 42 Choay J, Petitou M, Lormeau JC, Sinaÿ P, Casu B, Gatti G. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116 (02) 492-499
    CrossrefPubMedGoogle Scholar
  • 43 Petitou M, Duchaussoy P, Herbert JM. et al. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa. Semin Thromb Hemost 2002; 28 (04) 393-402
    Article in Thieme ConnectPubMedGoogle Scholar
  • 44 Samama M-M, Gerotziafas GT. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Res 2003; 109 (01) 1-11
    CrossrefPubMedGoogle Scholar
  • 45 Bauer KA, Hawkins DW, Peters PC. et al. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors. Cardiovasc Drug Rev 2002; 20 (01) 37-52
    CrossrefPubMedGoogle Scholar
  • 46 Yusuf S, Mehta SR, Chrolavicius S. et al; Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354 (14) 1464-1476
    CrossrefPubMedGoogle Scholar
  • 47 Coppens M, Eikelboom JW, Gustafsson D, Weitz JI, Hirsh J. Translational success stories: development of direct thrombin inhibitors. Circ Res 2012; 111 (07) 920-929
    CrossrefPubMedGoogle Scholar
  • 48 Gustafsson D, Bylund R, Antonsson T. et al. A new oral anticoagulant: the 50-year challenge. Nat Rev Drug Discov 2004; 3 (08) 649-659
    CrossrefPubMedGoogle Scholar
  • 49 Halperin JL. Executive Steering Committee, SPORTIF III and V Study Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003; 146 (03) 431-438
    CrossrefPubMedGoogle Scholar
  • 50 Olsson SB. Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362 (9397): 1691-1698
    CrossrefPubMedGoogle Scholar
  • 51 Albers GW, Diener HC, Frison L. et al; SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005; 293 (06) 690-698
    CrossrefPubMedGoogle Scholar
  • 52 Evans HC, Perry CM, Faulds D. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery. Drugs 2004; 64 (06) 649-678
    CrossrefPubMedGoogle Scholar
  • 53 Schulman S. The role of ximelagatran in the treatment of venous thromboembolism. Pathophysiol Haemost Thromb 2005; 34 (Suppl. 01) 18-24
    CrossrefPubMedGoogle Scholar
  • 54 Gurewich V. Ximelagatran–promises and concerns. JAMA 2005; 293 (06) 736-739
    CrossrefPubMedGoogle Scholar
  • 55 Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol 2010; (196) 407-418
    CrossrefPubMedGoogle Scholar
  • 56 Steffel J, Collins R, Antz M. et al; External Reviewers. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace 2021; 23 (10) 1612-1676
    Google Scholar
  • 57 Ortel TL, Neumann I, Ageno W. et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4 (19) 4693-4738
    CrossrefPubMedGoogle Scholar
  • 58 Chin PKL, Vella-Brincat JWA, Barclay ML, Begg EJ. Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles?. Br J Clin Pharmacol 2012; 74 (05) 734-740
    CrossrefPubMedGoogle Scholar
  • 59 Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012; 366 (09) 864-866
    CrossrefPubMedGoogle Scholar
  • 60 Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013; 368 (14) 1272-1274
    CrossrefPubMedGoogle Scholar
  • 61 Mitchell A, Snowball J, Welsh TJ, Watson MC, McGrogan A. Prescribing of direct oral anticoagulants and warfarin to older people with atrial fibrillation in UK general practice: a cohort study. BMC Med 2021; 19 (01) 189
    CrossrefPubMedGoogle Scholar
  • 62 Wheelock KM, Ross JS, Murugiah K, Lin Z, Krumholz HM, Khera R. Clinician trends in prescribing direct oral anticoagulants for US Medicare beneficiaries. JAMA Netw Open 2021; 4 (12) e2137288
    CrossrefPubMedGoogle Scholar
  • 63 Favaloro EJ, Pasalic L, Lippi G. Replacing warfarin therapy with the newer direct oral anticoagulants, or simply a growth in anticoagulation therapy? Implications for pathology testing. Pathology 2017; 49 (06) 639-643
    CrossrefPubMedGoogle Scholar
  • 64 Menichelli D, Del Sole F, Di Rocco A. et al. Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605 771 patients. Eur Heart J Cardiovasc Pharmacother 2021; 7 (FI1): f11-f19
    CrossrefPubMedGoogle Scholar
  • 65 Hill NR, Sandler B, Bergrath E. et al. A systematic review of network meta-analyses and real-world evidence comparing apixaban and rivaroxaban in nonvalvular atrial fibrillation. Clin Appl Thromb Hemost 2020; 26 (Jan-Dec): 1076029619898764
    PubMedGoogle Scholar
  • 66 Aryal MR, Gosain R, Donato A. et al. Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. Blood Adv 2019; 3 (15) 2381-2387
    CrossrefPubMedGoogle Scholar
  • 67 Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI. Subcommittee on Control of Anticoagulation. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 2016; 14 (03) 623-627
    CrossrefPubMedGoogle Scholar
  • 68 Pollack Jr CV, Reilly PA, Eikelboom J. et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373 (06) 511-520
    CrossrefPubMedGoogle Scholar
  • 69 Pollack Jr CV, Reilly PA, van Ryn J. et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med 2017; 377 (05) 431-441
    CrossrefPubMedGoogle Scholar
  • 70 Siegal DM, Curnutte JT, Connolly SJ. et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015; 373 (25) 2413-2424
    CrossrefPubMedGoogle Scholar
  • 71 Connolly SJ, Crowther M, Eikelboom JW. et al; ANNEXA-4 Investigators. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019; 380 (14) 1326-1335
    CrossrefPubMedGoogle Scholar
  • 72 Kanjee Z, McCann ML, Freed JA. Availability of specific direct oral anticoagulant reversal agents in US hospitals. JAMA Netw Open 2021; 4 (05) e2110079
    CrossrefPubMedGoogle Scholar
  • 73 Tomaselli GF, Mahaffey KW, Cuker A. et al. 2020 ACC Expert Consensus Decision Pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2020; 76 (05) 594-622
    CrossrefPubMedGoogle Scholar
  • 74 de Vries TAC, Hirsh J, Xu K. et al. Apixaban for stroke prevention in atrial fibrillation: Why are event rates higher in clinical practice than in randomized trials? A Systematic review. Thromb Haemost 2020; 120 (09) 1323-1329
    Article in Thieme ConnectPubMedGoogle Scholar
  • 75 Zhang X-L, Zhang X-W, Wang T-Y. et al. Off-label under- and overdosing of direct oral anticoagulants in patients with atrial fibrillation: a meta-analysis. Circ Cardiovasc Qual Outcomes 2021; 14 (12) e007971
    CrossrefPubMedGoogle Scholar
  • 76 de Vries TAC, Hirsh J, Chan NC. Letter by de Vries et al regarding article “off-label under- and overdosing of direct oral anticoagulants in patients with atrial fibrillation: a meta-analysis”. Circ Cardiovasc Qual Outcomes 2022; 15 (05) e008982
    PubMedGoogle Scholar
  • 77 Chan N, Sager PT, Lawrence J. et al. Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?. Am Heart J 2018; 199: 59-67
    CrossrefPubMedGoogle Scholar
  • 78 de Vries TAC, Hirsh J, Bhagirath VC. et al. Can a single measurement of apixaban levels identify patients at risk of overexposure? A prospective cohort study. TH Open 2022; 6 (01) e10-e17
    Article in Thieme ConnectPubMedGoogle Scholar
  • 79 Eikelboom JW, Connolly SJ, Brueckmann M. et al; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369 (13) 1206-1214
    CrossrefPubMedGoogle Scholar
  • 80 Andreas M, Moayedifar R, Wieselthaler G. et al. Increased thromboembolic events with dabigatran compared with vitamin K antagonism in left ventricular assist device patients: a randomized controlled pilot trial. Circ Heart Fail 2017; 10 (05) e003709
    CrossrefPubMedGoogle Scholar
  • 81 Pengo V, Denas G, Zoppellaro G. et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018; 132 (13) 1365-1371
    CrossrefPubMedGoogle Scholar
  • 82 Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M. et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med 2019; 171 (10) 685-694
    CrossrefPubMedGoogle Scholar
  • 83 Woller SC, Stevens SM, Kaplan D. et al. Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. Blood Adv 2022; 6 (06) 1661-1670
    CrossrefPubMedGoogle Scholar
  • 84 Khairani CD, Bejjani A, Piazza G. et al. Direct oral anticoagulants vs vitamin-K antagonists in thrombotic antiphospholipid syndrome: meta-analysis of randomized controlled trials. J Am Coll Cardiol 2022; S0735-1097 (22) 07098-X
    PubMedGoogle Scholar
  • 85 Connolly SJ, Karthikeyan G, Ntsekhe M. et al; INVICTUS Investigators. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J Med 2022; 387 (11) 978-988
    Google Scholar
  • 86 Chan NC, Weitz JI, Eikelboom JW. Anticoagulation for mechanical heart valves: will oral factor Xa inhibitors be effective?. Arterioscler Thromb Vasc Biol 2017; 37 (05) 743-745
    CrossrefPubMedGoogle Scholar
  • 87 Jaffer IH, Fredenburgh JC, Hirsh J, Weitz JI. Medical device-induced thrombosis: what causes it and how can we prevent it?. J Thromb Haemost 2015; 13 (Suppl. 01) S72-S81
    CrossrefPubMedGoogle Scholar
  • 88 Jaffer IH, Stafford AR, Fredenburgh JC, Whitlock RP, Chan NC, Weitz JI. Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation. J Am Heart Assoc 2015; 4 (08) e002322
    CrossrefPubMedGoogle Scholar
  • 89 Nopp S, Kraemmer D, Ay C. Factor XI inhibitors for prevention and treatment of venous thromboembolism: a review on the rationale and update on current evidence. Front Cardiovasc Med 2022; 9: 903029
    CrossrefPubMedGoogle Scholar
  • 90 Weitz JI, Chan NC. Advances in antithrombotic therapy. Arterioscler Thromb Vasc Biol 2019; 39 (01) 7-12
    CrossrefPubMedGoogle Scholar
  • 91 De Caterina R, Prisco D, Eikelboom JW. Factor XI inhibitors: cardiovascular perspectives. Eur Heart J 2022; ehac464 DOI: 10.1093/eurheartj/ehac464.
    CrossrefPubMedGoogle Scholar
  • 92 Ginsberg JS, Davidson BL, Comp PC. et al; RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24 (01) 1-9
    CrossrefPubMedGoogle Scholar
  • 93 Eriksson BI, Dahl OE, Rosencher N. et al; RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5 (11) 2178-2185
    CrossrefPubMedGoogle Scholar
  • 94 Eriksson BI, Dahl OE, Rosencher N. et al; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370 (9591): 949-956
    CrossrefPubMedGoogle Scholar
  • 95 Eriksson BI, Dahl OE, Huo MH. et al; RE-NOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011; 105 (04) 721-729
    Article in Thieme ConnectPubMedGoogle Scholar
  • 96 Eriksson BI, Borris LC, Friedman RJ. et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358 (26) 2765-2775
    CrossrefPubMedGoogle Scholar
  • 97 Kakkar AK, Brenner B, Dahl OE. et al; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372 (9632): 31-39
    CrossrefPubMedGoogle Scholar
  • 98 Lassen MR, Ageno W, Borris LC. et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358 (26) 2776-2786
    CrossrefPubMedGoogle Scholar
  • 99 Turpie AG, Lassen MR, Davidson BL. et al; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373 (9676): 1673-1680
    CrossrefPubMedGoogle Scholar
  • 100 Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361 (06) 594-604
    CrossrefPubMedGoogle Scholar
  • 101 Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375 (9717): 807-815
    CrossrefPubMedGoogle Scholar
  • 102 Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363 (26) 2487-2498
    CrossrefPubMedGoogle Scholar
  • 103 Schulman S, Kearon C, Kakkar AK. et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 (24) 2342-2352
    CrossrefPubMedGoogle Scholar
  • 104 Schulman S, Kakkar AK, Goldhaber SZ. et al; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129 (07) 764-772
    CrossrefPubMedGoogle Scholar
  • 105 Bauersachs R, Berkowitz SD, Brenner B. et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
    CrossrefPubMedGoogle Scholar
  • 106 Büller HR, Prins MH, Lensin AW. et al; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
    CrossrefPubMedGoogle Scholar
  • 107 Agnelli G, Buller HR, Cohen A. et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
    CrossrefPubMedGoogle Scholar
  • 108 Büller HR, Décousus H, Grosso MA. et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
    CrossrefPubMedGoogle Scholar
  • 109 Schulman S, Kearon C, Kakkar AK. et al; RE-MEDY Trial Investigators, RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368 (08) 709-718
    CrossrefPubMedGoogle Scholar
  • 110 Agnelli G, Buller HR, Cohen A. et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368 (08) 699-708
    CrossrefPubMedGoogle Scholar
  • 111 Weitz JI, Lensing AWA, Prins MH. et al; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017; 376 (13) 1211-1222
    CrossrefPubMedGoogle Scholar
  • 112 Connolly SJ, Ezekowitz MD, Yusuf S. et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
    Google Scholar
  • 113 Patel MR, Mahaffey KW, Garg J. et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
    Google Scholar
  • 114 Granger CB, Alexander JH, McMurray JJ. et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
    Google Scholar
  • 115 Giugliano RP, Ruff CT, Braunwald E. et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
    Google Scholar
  • 116 Connolly SJ, Eikelboom J, Joyner C. et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364 (09) 806-817
    CrossrefPubMedGoogle Scholar
  • 117 Hori M, Matsumoto M, Tanahashi N. et al; J-ROCKET AF Study Investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study. Circ J 2012; 76 (09) 2104-2111
    CrossrefPubMedGoogle Scholar